Theravance Biopharma Inc (TBPH)
9.18
+0.34
(+3.85%)
USD |
NASDAQ |
May 02, 11:58
Theravance Biopharma Revenue (Quarterly): 17.56M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.56M |
| September 30, 2023 | 15.69M |
| June 30, 2023 | 13.75M |
| March 31, 2023 | 10.42M |
| December 31, 2022 | 14.65M |
| September 30, 2022 | 12.45M |
| June 30, 2022 | 11.05M |
| March 31, 2022 | 13.20M |
| December 31, 2021 | 14.95M |
| September 30, 2021 | 13.19M |
| June 30, 2021 | 12.91M |
| March 31, 2021 | 14.26M |
| December 31, 2020 | 18.73M |
| September 30, 2020 | 18.26M |
| June 30, 2020 | 15.01M |
| March 31, 2020 | 19.86M |
| December 31, 2019 | 29.50M |
| September 30, 2019 | 12.43M |
| June 30, 2019 | 26.15M |
| March 31, 2019 | 5.338M |
| December 31, 2018 | 15.74M |
| September 30, 2018 | 12.84M |
| Date | Value |
|---|---|
| June 30, 2018 | 23.48M |
| March 31, 2018 | 8.319M |
| December 31, 2017 | 4.515M |
| September 30, 2017 | 4.275M |
| June 30, 2017 | 3.509M |
| March 31, 2017 | 3.087M |
| December 31, 2016 | 5.692M |
| September 30, 2016 | 19.08M |
| June 30, 2016 | 5.471M |
| March 31, 2016 | 18.41M |
| December 31, 2015 | 3.893M |
| September 30, 2015 | 10.70M |
| June 30, 2015 | 7.134M |
| March 31, 2015 | 20.40M |
| December 31, 2014 | 1.433M |
| September 30, 2014 | 6.336M |
| June 30, 2014 | 2.974M |
| March 31, 2014 | 0.945M |
| December 31, 2013 | 0.175M |
| September 30, 2013 | 0.024M |
| June 30, 2013 | 0.005M |
| March 31, 2013 | 0.022M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
10.42M
Minimum
Mar 2023
29.50M
Maximum
Dec 2019
16.00M
Average
14.65M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 135.40M |
| Nektar Therapeutics | 23.88M |
| Vanda Pharmaceuticals Inc | 45.27M |
| Fate Therapeutics Inc | 1.676M |
| FibroGen Inc | 27.14M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.51M |
| Total Expenses (Quarterly) | 24.16M |
| EPS Diluted (Quarterly) | -0.17 |
| Enterprise Value | 323.35M |
| Profit Margin (Quarterly) | -48.45% |
| Earnings Yield | -10.57% |
| Normalized Earnings Yield | -10.24 |